Clinical Trial Update: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial of RO4929097, a gamma-secretase/Notch pathway inhibitor, in recurrent or progressive glioblastoma was terminated. Results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-03